

Isotretinoin musculoskeletal side effects: a systematic review

Rahaf R. Almutairi,¹ Atheer G. Almutairi,² Afnan F. Alhallafi,¹ Norah A. Almudawi,¹ Mohammed Abdulaziz AlSulaiman,³ Asem M. Shadid,⁴ Ruaa Alharxithy^{3,5}

¹College of Medicine, Imam Mohammed bin Saud Islamic University; ²Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah; ³Division of Dermatology, Security Forces Hospital, Riyadh; ⁴Department of Dermatology, King Fahad Medical City; ⁵Princess Nourah Bint Abdul Rahman University, Riyadh, Kingdom of Saudi Arabia

Abstract

This study aimed to investigate musculoskeletal complications secondary to isotretinoin use. A systematic review was conducted, and a total of 49 studies, including analytical studies, case reports, and case series, were included in the analysis. The studies examined musculoskeletal symptoms, diagnostic findings, and treatment approaches associated with isotretinoin use. Musculoskeletal symptoms reported in the studies included lethargy, myalgia, low back pain, arthralgia, tendinopathy, and sacroiliitis. Physical examination findings and radiological findings were used to confirm the diagnoses. Treatment approaches ranged from [non-steroidal anti-inflammatory drugs (NSAIDs)] to discontinuation of isotretinoin. Some studies have explored the impact of isotretinoin dosage, treatment duration, and vitamin levels on musculoskeletal symptoms. Isotretinoin-induced sacroiliitis and [diffuse idiopathic skeletal hyperostosis (DISH)] emerged as notable musculoskeletal complications. The findings highlight the importance of monitoring patients for potential musculoskeletal side effects and implementing appropriate interventions.

Correspondence: Atheer G. Almutairi, Unaizah College of Medicine and Medical Sciences, Qassim University, Eastern Ring Road, Unaizah, 51911, Kingdom of Saudi Arabia.

Tel.: +966.533498281.

E-mail: AtheerAlmutairi16@gmail.com

Key words: Isotretinoin; acne; musculoskeletal side effects; arthritis; myositis.

Contributions: the authors contributed equally.

Conflict of interest: the authors declare no potential conflict of interest.

Funding: None.

Received: 8 September 2023.

Accepted: 4 February 2024.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2024

Licensee PAGEPress, Italy

Dermatology Reports 2024; 16:9845

doi:10.4081/dr.2024.9845

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Introduction

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit, as well as one of the most widespread health issues dermatologists repeatedly face, influencing many people at some point in their lives.¹⁻³

Severe acne vulgaris can have a profound impact on an individual's quality of life, causing physical discomfort, psychological distress, and social stigma.² Acne affects up to 50 million Americans annually, and its severity can range from mild, with comedones and pustules, to severe, with deep nodules and cysts.⁴ Isotretinoin, a synthetic derivative of vitamin A, has been widely used as an effective treatment for severe acne vulgaris since its introduction in the early 1980s.⁵⁻⁷ Its remarkable success in treating this dermatological condition has made it a popular choice among physicians and patients alike.⁸ However, despite its efficacy, isotretinoin use is associated with a range of potential side effects, including those affecting the musculoskeletal system.^{5,9-11} They can manifest as generalized or localized symptoms, ranging from mild discomfort to severe debilitating conditions. One of the most commonly reported musculoskeletal side effects of isotretinoin is musculoskeletal pain.¹⁰ Reports of musculoskeletal adverse events associated with isotretinoin use have been described in the medical literature, although their prevalence and significance remain topics of debate.^{9,10} This systematic review aims to comprehensively analyze the existing literature to better understand the nature and prevalence of isotretinoin-induced musculoskeletal adverse events (Table 1).

Methodology

Study design

This study was designed following the [Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (PRISMA)].

Search strategy

We conducted a literature search of the PubMed and Google Scholar databases for all relevant studies published between 1989 and 2022. We used the following keywords: "isotretinoin," "arthritis," "myositis," "backache," and "musculoskeletal side effects." Four investigators (R.M., A.M., N.M., and A.H.) independently screened the search results for inclusion in the study. We included studies that met the following criteria: (1) articles published between 2000 and 2022, (2) a study population of males and females above 12 years old, and (3) the study population was treated for acne vulgaris with no other comorbidities. We excluded non-English studies, systematic reviews, review articles, expert opinions, studies conducted on animals, and studies that did not provide adequate information.

Data extraction

Two authors (A. H. and N.M.) independently extracted data from the included studies using a standardized data extraction form. We collected the following data: author, publication year, study design, sample size, age of the patient, sex, isotretinoin dose (of symptoms), onset of the symptoms, initial presentation, physical examination findings, laboratory/pathological/radiological findings, medical history, family history, drug and supplement intake, smoking status, and symptoms after dose reduction. Discrepancies in the data extraction were resolved by the third author (R.M.).

Data synthesis

We synthesized the data from the included studies to provide a comprehensive overview of the musculoskeletal side effects of isotretinoin use. Qualitative data synthesis was performed on the included studies.

Results

Search results

A total of 1,089 articles were initially identified through the search process. After removing 51 duplicates, 1,038 articles remained for screening. The screening phase involved a thorough assessment of the titles and abstracts of the identified articles. After this initial screening, 73 articles were selected for full-text assessment based on their potential relevance to the study objectives. During the full-text assessment, each of the 73 articles was carefully evaluated to determine their eligibility for inclusion in the study. Following this assessment, 49 studies were deemed suitable and included in the analysis. The included studies comprised various study designs, including analytical studies (Supplementary Table 1, n=13),¹²⁻²⁴ case reports (Supplementary

Table 2, n=28),²⁵⁻⁵² and case series (Supplementary Table 3, n=8, with a total of 54 cases).⁵³⁻⁶¹

The PRISMA flow diagram below shows a visual representation of the article selection process (Figure 1).

Characters and findings of the included analytical studies

Supplementary Table 1 provides a summary of the findings from 13 analytical studies on [musculoskeletal (MSK)] side effects associated with isotretinoin treatment. The studies focused on the relationship between the dose, HLA-B27 status, and MSK side effects, as well as MSK side effects among athletes taking isotretinoin. The age of the patients ranges from 16.2 to 25 years. The most commonly reported symptoms included back pain, myalgia (muscle pain), arthralgia (joint pain), and sacroiliitis. Back pain was the predominant symptom, reported in 41% to 74% of cases, followed by myalgia and arthralgia. Other symptoms such as lethargy, hip pain, weakness, and Achilles enthesopathy were also mentioned in some studies. However, the frequencies of these symptoms were not consistently provided across all studies. Information regarding the specific doses of isotretinoin used varied among the studies. Reported dosages ranged from as low as 0.25 mg/kg to as high as 2 mg/kg per day. In some studies, the dosage was reported as a range or a median value, while in others, a mean or a specific daily dose was mentioned. Cumulative doses were also reported in some studies, ranging from 120 to 150 mg/kg.

Characteristics and findings of the included case reports

Supplementary Table 2 provides information on the characteristics of the included case reports, including age, sex, initial presentation, isotretinoin dose, onset of symptoms, diagnosis, and symptoms after dose reduction. The age range of the patients varies from 15 to 55 years, with a mean age of approximately 25.4

Table 1. Adverse events by number of patients.

Symptoms	Number of patients
Sacroiliitis	113
Inflammatory Back pain	106
Mechanical back pain	212
Arthralgia	56
Arthritis	3
Lethargy	98
Myalgia	149
Achilles tendinopathy	8
CK elevation Creatinine Kinase	46
Diffuse idiopathic skeletal hyperostosis (DISH)	2
ACL lesion Anterior Cruciate ligament	1
Septic subacromial bursitis	1
Abscesses on the scalp	1
Fluctuant nodules	1
Sensorimotor demyelinating polyneuropathy	1
Knee pain	1
Hip osteoarthritis (OA)	2
Mild non-inflammatory pain affecting the cervical and thoracic spine.	1
Chest pain	1
Rhabdomyolysis	1

CK, Creatinine Kinase, AC, lesion Anterior Cruciate ligament.

years. Among the reported cases, 17 were male (60.7%), and 11 were female (39.3%). The most common presentations include severe back pain (3 cases), bilateral hip pain (2 cases), wrist and MCP joint pain (2 cases), groin pain (1 case), myalgia and low back pain (1 case), acne fulminans with inflammatory lesions (1 case), and other specific symptoms in the remaining cases. The prescribed isotretinoin doses varied among the reported cases. In some cases, the initial dose was mentioned explicitly, while in others, it was not specified or the cumulative dose couldn't be confirmed. The reported daily doses ranged from 20 mg to 500 mg/kg/day, with the majority of cases receiving doses in the range of 20 mg to 40 mg per day. In some instances, symptoms appeared shortly after treatment, while in others, they developed months or even years later. The exact onset of symptoms was not mentioned for a few cases. Based on the case reports, various diagnoses were made for the patients' symptoms. The reported diagnoses include bilateral sacroiliitis and left hip arthritis, isotretinoin-induced arthritis and sacroiliitis, rhabdomyolysis, chronic sacroiliitis, acne-associated musculoskeletal syndrome, acute hip monoarthritis, diffuse idiopathic skeletal hyperostosis (DISH), acute subacromial bursitis or calcific tendinitis, retinoid-induced sclerosis, polyneuropathy, retinoid-induced premature epiphyseal closure, non-union distal fibula avulsion fracture, skeletal hyperostosis, and acute sacroiliitis. The information regarding symptoms after dose reduction or discontinuation of isotretinoin was available for some cases. In many instances, symptoms improved or resolved completely after reducing the dose or stopping the treatment. However, in a few cases, symptoms persisted or recurred even after discontinuation.

Characteristics and findings of the included case series

Supplementary Table 3 provides an overview of the case series, each row in the table represents an individual case, and various

parameters are recorded for analysis. Among the 54 cases, 50% were male and 50% were female. The age range of the patients was between 15 and 44 years. Regarding the initial presentation, the most commonly reported symptom was back pain (74%), followed by hip pain (39%) and joint pain (17%). Other symptoms included neck pain, chest pain, gluteal pain, and knee pain. In some cases, the symptoms were accompanied by morning stiffness. In some cases, the initial presentation was missing. The reported doses ranged from 10 mg to 120 mg per day. However, some studies did not specify the exact dosage. In some cases, the dosage was increased during the course of treatment. The duration of treatment with isotretinoin ranged from 1 month to 7 years. The onset of symptoms after the initiation or discontinuation of isotretinoin also varied among the cases. Symptoms were reported to occur as early as 15 days after initiation and as late as 16 years after treatment. Similarly, symptoms resolved at different time points after discontinuation, ranging from a few weeks to several months. The most commonly reported diagnosis was isotretinoin-induced sacroiliitis (63%). Other reported diagnoses included costochondritis, sacroiliitis, and active sacroiliitis. In some cases, the diagnosis was not specified. It is important to note that not all studies provided detailed information about the diagnosis. After dose reduction or discontinuation of isotretinoin, the majority of cases showed improvement or complete resolution of symptoms. In some cases, additional treatment with medications such as adalimumab or non-steroidal anti-inflammatory drugs (NSAIDs) was required to achieve symptom relief. However, a small number of cases did not show complete resolution of symptoms even after treatment.

Discussion

This systematic review aimed to investigate the [musculoskeletal (MSK)] side effects associated with isotretinoin treatment. The analysis included a total of 49 studies, consisting of analytical studies, case reports, and case series. The analytical studies included in this review focused on different aspects of MSK side effects associated with isotretinoin treatment. The studies varied in sample size, ranging from 15 to 154 patients, and included both male and female participants with varying age ranges. The reported musculoskeletal symptoms included lethargy, myalgia, low back pain, arthralgia, tendinopathy, sacroiliitis, and other MSK side effects. Some studies have distinguished between inflammatory and mechanical low back pain, highlighting the nature of the pain. Isotretinoin doses administered in the studies ranged from 0.25 to 0.8 mg/kg/day, with variations in cumulative doses. The onset of symptoms occurred within a few months of treatment initiation.

The studies examined the relationship between isotretinoin use and musculoskeletal side effects, focusing on factors such as dose, HLA-B27 status, and their impact on the occurrence and severity of symptoms.

The physical examination findings reported in the studies included features such as sacroiliac joint tenderness, muscle weakness, and erythema. Radiological findings, such as sacroiliac joint X-rays or MRI, were utilized to confirm diagnoses of sacroiliitis and other related conditions. The diagnosis of musculoskeletal conditions varied across the studies, encompassing mechanical back pain, inflammatory back pain, tendinopathy, sacroiliitis, hyperCKemia (elevated CK levels), and others. Treatment approaches ranged from the use of NSAIDs to the discontinuation of isotretinoin, depending on the severity of the symptoms. Some studies have also explored potential risk factors or associations by




Figure 1. PRISMA flow diagram summarizing the search and screening process.

assessing the medical history of chronic diseases, family history, and smoking status. Additionally, investigations into the impact of isotretinoin dosage, treatment duration, and vitamin levels on musculoskeletal symptoms and laboratory markers were conducted. Among the individual studies, Selçuk *et al.*¹² reported musculoskeletal symptoms, such as lethargy, myalgia, and low back pain, in a study involving 73 individuals aged 15–34 years. Acute sacroiliitis was observed in 8.2% of the cases, and no significant pathology was found in the laboratory findings. Karaosmanoğlu and Mülkoğlu¹³ examined 94 participants with a mean age of 20.8 years who reported musculoskeletal symptoms, including arthralgia, myalgia, low back pain, and sacroiliitis. Sacroiliitis was observed in 11.7% of the cases, while radiological and laboratory findings did not reveal significant pathology. Acar *et al.*¹⁴ investigated 99 individuals with a mean age of 20.5 years, reporting back pain, inflammatory back pain, and mechanical back pain as musculoskeletal symptoms. Among the reported cases, isotretinoin-induced sacroiliitis emerged as a notable musculoskeletal complication. Several cases, such as those presented by Yılmaz *et al.*²⁶, Bilecik *et al.*³⁵, Toledo *et al.*³⁶, Cheng *et al.*³⁷, Levinson *et al.*⁴⁵, and Kibar *et al.*⁴⁹, described individuals who developed sacroiliitis after isotretinoin treatment. Encouragingly, the symptoms either resolved or improved upon discontinuation of the medication or with the use of anti-inflammatory medications. These findings underscore the importance of monitoring patients undergoing isotretinoin therapy for potential sacroiliitis symptoms and implementing appropriate interventions when necessary. Another musculoskeletal complication identified in the case reports was DISH. A case presented by Zhao and Goodson³⁸ exemplified a patient who experienced thoracic back pain and morning stiffness following one year of isotretinoin treatment. Although complete resolution of symptoms was not achieved, they showed improvement with the use of gabapentin. Similarly, Barceló *et al.*⁴⁰ reported a case of DISH in a female patient after 11 years of isotretinoin use. These cases suggest a potential association between isotretinoin and DISH, highlighting the need for further investigation and monitoring of patients on long-term isotretinoin therapy.

The case reports also revealed other musculoskeletal complications associated with isotretinoin use. Drezner and Sennett⁴¹ described a case of acute subacromial bursitis or calcific tendinitis in a female patient presenting with shoulder pain that improved with antibiotics. Atalay *et al.*⁴² reported a case of arthralgia and elevated serum ALP levels, leading to a diagnosis of retinoid-induced sclerosis and a gradual decline in bone mineral density. Eksioğlu *et al.*⁴³ presented a case of bilateral hip pain that completely resolved after three months of isotretinoin treatment. These cases provide further insights into the diverse musculoskeletal effects associated with isotretinoin use, highlighting the importance of recognizing and managing such complications in clinical practice.

Overall, the included case reports collectively contribute to our understanding of the musculoskeletal effects of isotretinoin. While the presented cases demonstrate a range of musculoskeletal complications, it is important to note that many of the reported symptoms improved or resolved with appropriate interventions, such as discontinuing the medication or administering anti-inflammatory drugs. These findings emphasize the significance of vigilant monitoring and prompt intervention to mitigate potential musculoskeletal side effects in individuals undergoing isotretinoin treatment. Among the case series, isotretinoin-induced sacroiliitis emerged as a significant musculoskeletal complication. Several studies have reported cases in which patients developed sacroiliitis after starting isotretinoin treatment. Notably, the symptoms of sacroiliitis typically appeared after a few months of treatment, and

discontinuing isotretinoin led to symptom resolution in most cases. This suggests a potential causal relationship between isotretinoin and sacroiliitis. The studies by Özdel *et al.*⁵³, Bilge *et al.*⁵⁴, Aydog *et al.*⁵⁵, Kavadar *et al.*⁵⁸, and Yavuz Pehlivan *et al.*⁵⁹ provide compelling evidence for this association. Furthermore, the cases described in these studies demonstrate the importance of recognizing sacroiliitis symptoms and implementing appropriate management strategies, such as discontinuing medication or using anti-inflammatory agents.

The case series by Özdel *et al.*⁵³ investigated two cases, both of which experienced hip and back pain as initial presentations. Isotretinoin-induced sacroiliitis manifested after different durations of treatment, but symptom improvement was not achieved until adalimumab was administered. This highlights the potential efficacy of adalimumab in managing isotretinoin-induced musculoskeletal symptoms. Manfredini *et al.*⁵⁷ focused on abnormal CK levels that exceeded the reference range in several patients. Although these cases did not present other musculoskeletal symptoms, they suggest that isotretinoin treatment may lead to elevated CK levels, those findings are also consistent to Faygia *et al.*⁵⁸. Kavadar *et al.*⁵⁹ described cases of lumbar and hip pain, walking difficulties, and morning stiffness that resolved completely upon discontinuation of isotretinoin. These cases provide further evidence of the association between isotretinoin use and sacroiliitis. Yavuz Pehlivan *et al.*⁶⁰ reported cases of backache, hip joint pain, and morning stiffness. The symptoms appeared after a certain duration of isotretinoin treatment, and while specific details regarding symptom resolution were not provided, it can be inferred that the symptoms gradually improved over time. Bilge *et al.*⁵⁴ reported multiple cases demonstrating complete resolution of symptoms upon discontinuation of isotretinoin. These cases involved individuals who experienced symptoms such as costochondritis, sacroiliitis, and painful sacroiliac joint symptoms, underscoring the importance of promptly recognizing and managing these complications. Aydog *et al.*⁵⁵ presented several cases in which lumbar back pain and active sacroiliitis were observed. Discontinuation of isotretinoin led to the resolution of symptoms, further supporting the association between isotretinoin use and the development of active sacroiliitis.

In terms of MSK side effects in relation to dose, several studies have examined the cumulative dose of isotretinoin and its association with different MSK symptoms. Selçuk *et al.*¹² reported that low back pain symptoms developed in 2–3 months of treatment with a mean isotretinoin dose of 0.53 mg/kg/day. Karaosmanoğlu and Mülkoğlu¹³ found a significant linear relationship between low back pain and a cumulative dose of isotretinoin. Acar *et al.*¹⁴ observed that the mean cumulative isotretinoin dose was significantly higher in patients with moderate and severe back pain than in those with mild back pain. These findings suggest that there may be a dose-dependent relationship between isotretinoin and MSK side effects, particularly low back pain.

Regarding HLA-B27 and MSK side effects, Karaosmanoğlu and Mülkoğlu¹³ reported that there was no significant difference in the total cumulative isotretinoin dose between patients with inflammatory back pain and those with mechanical back pain. This suggests that HLA-B27 status may not play a significant role in the development of MSK side effects in patients taking isotretinoin. However, it is important to note that this finding is based on a single study, and further research is needed to confirm this relationship. Kaymak¹⁹ found that out of 89 patients treated with isotretinoin, only 11 experienced myalgia and weakness, and 8 of them were athletes. This study suggests that strenuous physical activity prior to isotretinoin treatment may increase the risk of

MSK side effects. It is important for athletes and individuals engaging in high-intensity physical activities to be aware of these potential risks and to discuss them with their healthcare providers. The cumulative dose of isotretinoin may be associated with the development and severity of MSK side effects, specifically low back pain. However, the relationship between HLA-B27 status and MSK side effects requires further investigation.

Strengths

This study conducted a systematic review to ensure a comprehensive evaluation of the available literature on musculoskeletal complications associated with isotretinoin use. The inclusion of various study designs provided a broader perspective on the topic. The study included numerous studies, enhancing the robustness and reliability of the findings. The analysis explored a range of musculoskeletal symptoms, diagnostic findings, and treatment approaches, contributing to a better understanding of isotretinoin-related musculoskeletal complications.

Limitations

The analysis was based on existing studies, which may have variations in methodology, sample sizes, and reporting biases. The included studies comprised various study designs, which may have introduced heterogeneity in the analysis.

Conclusions

The study findings indicate that musculoskeletal side effects, such as low back pain, myalgia, and arthralgia, are common among patients using isotretinoin. Isotretinoin-induced sacroiliitis and DISH were identified as significant complications. The cumulative dose of isotretinoin may be associated with the development and severity of musculoskeletal side effects, particularly low back pain. However, further research is needed to investigate the relationship between HLA-B27 status and musculoskeletal side effects. The study emphasizes the importance of monitoring patients undergoing isotretinoin therapy for potential musculoskeletal complications and of implementing appropriate interventions when necessary. Overall, this study provides valuable insights into the musculoskeletal complications associated with isotretinoin use and highlights the need for further research and clinical monitoring in this area.

References

- Well D. Acne vulgaris: A review of causes and treatment options. *Nurse Pract* 2013;38:22–31; quiz 32.
- Gallitano SM, Berson DS. How Acne Bumps Cause the Blues: The Influence of Acne Vulgaris on Self-Esteem. *Int J Womens Dermatol* 2018;4:12–7.
- Williams HC, Dellavalle RP, Garner S. Acne vulgaris. *Lancet* 2012;379:361–72.
- Tan JKL, Bhat K. A global perspective on the epidemiology of acne. *Br J Dermatol* 2015;172Suppl:3–12.
- Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. *J Am Acad Dermatol* 2001;45:S150–7.
- Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. *J Am Acad Dermatol* 1984;10:490–6.
- Choi JS, Koren G, Nulman I. Pregnancy and isotretinoin therapy. *CMAJ* 2013;185:411–3.
- Strauss JS, Stranieri AM. Changes in long-term sebum production from isotretinoin therapy. *J Am Acad Dermatol* 1982;6:751–6.
- Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. *Cutis* 1984;33:484–486,489.
- McLane J. Analysis of common side effects of isotretinoin. *J Am Acad Dermatol* 2001;45:S188–94.
- Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. *Semin Cutan Med Surg* 2008;27:197–206.
- Baykal Selçuk L, Aksu Arica D, Baykal Şahin H, et al. The prevalence of sacroiliitis in patients with acne vulgaris using isotretinoin. *Cutan Ocul Toxicol* 2017;36:176–9.
- Karaosmanoğlu N, Mülkoğlu C. Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study. *BMC Musculoskelet Disor* 2020;21:631.
- Acar EM, Şaş S, Koçak FA. Evaluation of musculoskeletal adverse effects in patients on systemic isotretinoin treatment: A cross-sectional study. *Arch Rheumatol* 2022;37:223–9.
- Alkan S, Kayiran N, Zengin O, et al. Isotretinoin-induced Spondyloarthritis-related Symptoms: A Prospective Study. *J Rheumatol* 2015;42:2106–9.
- Ertugrul DT, Karadag AS, Tural E, Akin KO. Therapeutic hotline. Does isotretinoin have effect on vitamin D physiology and bone metabolism in acne patients? *Dermatol Ther* 2011;24:291–5.
- Taheri A, Sabouhi S, Farazmand F. Incidence of low back pain and sacroiliitis in military families with acne vulgaris under isotretinoin therapy. *Am J Clin Exp Immunol* 2020;9:6–9.
- Ghiyasi M, Lajevardi V, Mortazavi H, Damavandi MR. Creatine phosphokinase values and myalgia during isotretinoin therapy. *Iran J Dermatol* 2013.
- Kaymak Y. Creatine phosphokinase values during isotretinoin treatment for acne. *Int J Dermatol*. 2008;47:398–401.
- Sayar SK. Elevated serum creatine kinase levels in acne vulgaris patients treated with isotretinoin: A retrospective single-center study. *Turk J Dermatol* 2021;15:1 [Internet]. [cited 2023 Jun 26] Available from: <https://www.tjonline.org/article.asp?issn=1307-7635;year=2021;volume=15;issue=1;page=1;epage=4;aulast=Sayar>
- Yıldızgören MT, Karatas Togral A, Baki AE, et al. Effects of isotretinoin treatment on cartilage and tendon thicknesses: an ultrasonographic study. *Clin Rheumatol* 2015.
- Ekiz T. Effects of isotretinoin treatment on cartilage and tendon thicknesses: an ultrasonographic study. *Clin Rheumatol* 2015;34:1255–8.
- Elnady B, Elkhoully T, Dawoud NM, et al. New onset of axial spondyloarthritis in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. *Clin Rheumatol* 2020;39:1829–38.
- DiGiovanna JJ, Langman CB, Tschen EH, et al. Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. *J Am Acad Dermatol* 2004;51:70917.
- Mülkoğlu C, Karaosmanoğlu N. Effect of oral isotretinoin on muscle strength in patients with acne vulgaris: a prospective controlled study. *BMC Pharmacol Toxicol* 2021;22:17.
- Kulaklı S, Kulaklı F, İlhanlı İ, Tatlı S, Çelik C. Bilateral sacroiliitis and left hip arthritis secondary to isotretinoin treatment. *The European Research Journal* [Internet]. 2019;5 [cited 2023 Jun 26] Available from: <https://dergipark.org.tr/en/pub/eurj/issue/40357/421976>.
- Yilmaz Tasdelen O, Yurdakul FG, Duran S, Bodur H. Isotretinoin-induced arthritis mimicking both rheumatoid arthritis and axial spondyloarthritis. *Int J Rheum Dis* 2015;18:466–9.
- Shimabuco A, Bertacini De Moraes J, Sampaio-Barros P, et al. A cross-sectional evaluation of a Brazilian spondyloarthritis single-

- center tertiary cohort: clinical and treatment data. 2018.
29. Dasgupta K, Lim P, Reedstorm H. A Common Drug With a Dangerous Side Effect: Acute Rhabdomyolysis Caused by the Synergistic Effect of Isotretinoin and Exercise in an Adolescent. *Cureus* 2020;12:e10929.
 30. Mülkoğlu C, Nacı B. A patient with chronic sacroiliitis undiagnosed for three years after isotretinoin use. *BMC Musculoskeletal Disord* 2020;21:300.
 31. McCarthy J. Retin-Aching: Hip and Back Pain in a Young Adult Male. In: 2014 AAP National Conference and Exhibition. American Academy of Pediatrics; 2014.
 32. Haskin O, Amir J, Kornreich L, et al. [Acne--merely a cosmetic problem? Acne associated musculoskeletal syndromes]. *Harefuah* 2008;147:12-15,96.
 33. Mahou, & Sailer. (n.d.). Acute Hip Monoarthritis in a Patient Treated With Isotretinoin. *J Clin Rheumatol* 2006;12:105-6.
 34. Barbareschi M, Paresce E, Chiaratti A, et al. Unilateral sacroiliitis associated with systemic isotretinoin treatment. *Int J Dermatol* 2010;49:331-3.
 35. Yilmazer B, Coşan F, Cefle A. Bilateral acute sacroiliitis due to isotretinoin therapy: a case report. Vol. 16, *Int J Rheum Dis* 2013;16:604-5.
 36. Bilecik NA, Tuna S, Alan S. AB0724 Isotretinoin Induced Bilateral Sacroiliitis: Case Report [Internet]. *Ann Rheum Dis* 2014;73(Suppl 2):1-1043. [cited 2023 Jun 26] Available from: https://www.researchgate.net/publication/286131813_AB0724_Isotretinoin_Induced_Bilateral_Sacroiliitis_CASE_Report.
 37. Toledo GJ, Gomes Polo M, Carolina A, et al. Case Report: Acute Bilateral Sacroiliitis due to the Use of Oral Isotretinoin. *Health Science Journal* [Internet] 2021;15. [cited 2023 Jun 26] Available from: <https://www.itmedicalteam.pl/articles/case-report-acute-bilateral-sacroiliitis-due-to-the-use-of-oral-isotretinoin-106279.html>.
 38. Cheng CW, Chien KJ, Cheng MF, Nong BR. Isotretinoin-induced sacroiliitis: A rare case report. *Pediatrics and neonatology* 2020;61:565-6.
 39. Zhao S, Goodson NJ. (2015). Diffuse idiopathic skeletal hyperostosis and isotretinoin in cystic acne. *BMJ case reports* 2015;2015:bcr2015209775.
 40. Marcheggiani Muccioli GM. Double ACL reconstruction failure in a young soccer player in treatment with retinoids: A case report. *Biomed J Sci Tech Res* 2019;16.
 41. Barceló MI, Vila Mas AT, Estremera Rodrigo A, Juan Mas A. (2021). Long term skeletal changes in a young woman treated with isotretinoin. *J Dermatol Skin Sci* 2021;3:23-5.
 42. Drezner JA, Sennett BJ. Subacromial/subdeltoid septic bursitis associated with isotretinoin therapy and corticosteroid injection. *J Am Board Fam Pract* 2004;17:299-302.
 43. Atalay A, Altaykan A, Ergin G, Kutsal YG. Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy. *Rheumatol Int* 2004;24:297-300.
 44. Eksioğlu E, Oztekin F, Unlu E, et al. Sacroiliitis and polyneuropathy during isotretinoin treatment. *Clin Exp Dermatol* 2008;33:122-4.
 45. Luthi F, Eggel Y, Theumann N. Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain. *Joint Bone Spine* 2012;79:314-6.
 46. Levinson M, Gibson A, Stephenson G. Sacroiliitis secondary to isotretinoin. *Australas J Dermatol* 2012;53:298-300.
 47. Constantinou M, Brown M. Non-union distal fibula avulsion fracture in a 16 year old male: A clinical case report [Internet]. *J Sci Med Sport* 2012;15:S135. [cited 2023 Jun 26] Available from: <http://www.jsams.org/article/S1440244012005373/fulltext>.
 48. Hartung B, Merk HF, Huckenbeck W, et al. Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin. *Int J Legal Med* 2012;126:953-6.
 49. Graf SW, Whittle SL. Isotretinoin-induced skeletal hyperostosis. *Springerplus*. 2014;3:698.
 50. Kibar S, Gündüz Ö, Ayanoğlu BT. Isotretinoin-induced Unilateral Sacroiliitis in a Patient with a Family History of Ankylosing Spondylitis and HLA B27 Positivity: A Case Report. *West Indian Med J* 2016.
 51. Rozin AP, Kagna O, Shiller Y. Sacroiliitis and severe disability due to isotretinoin therapy. *Rheumatol Int* 2010;30:985-6.
 52. Yılmaz Tasdelen O, Yurdakul FG, Duran S, Bodur H. Isotretinoin-induced arthritis mimicking both rheumatoid arthritis and axial spondyloarthritis. *Int J Rheum Dis* 2015;18:466-69.
 53. Gökbel T, Gözpinar G, Dursun N, Dursun E. Isotretinoin Treatment-Induced Sacroiliitis [Internet]. *Türkiye Klinikleri J Case Rep* 2021;29:94-7. [cited 2023 Jun 26] Available from: <https://www.turkiyeklinikleri.com/article/tr-isotretinoin-treatment-induced-sacroiliitis-92356.html>.
 54. Ozdel S, Baglan E, Kargın Cakıcı E, et al. Two pediatric cases of isotretinoin-induced sacroiliitis successfully treated with adalimumab. *Pediatric dermatology* 2020;37:929-31.
 55. Yaşar Bilge NS, Kaşifoğlu T, Korkmaz C. AB0682 A Rare Adverse Effect of Isotretinoin Treatment: Sacroiliitis: Table 1 [Internet]. *Ann Rheum Dis* 2014;73(Suppl 2):1030.4-1031. [cited 2023 Jun 26] Available from: https://www.researchgate.net/publication/286244043_AB0682_A_Rare_Adverse_Effect_of_Isotretinoin_Treatment_Sacroiliitis.
 56. Aydog E, Ozturk G, Comert A, et al. Sacroiliitis during isotretinoin treatment: causal association or coincidence? *North Clin Istanbul* 2018;6:75-80.
 57. Dincer U, Cakar E, Kiralp M, Dursun H. Can Isotretinoin Induce Sacroiliitis: Three Cases. *Turkish J Rheumatol* 2008;23.
 58. Manfredini M, Bettoli V, Forconi R, et al. Creatine Phosphokinase Values during Low Starting Dose Isotretinoin Therapy. *Skin Appendage Disord* 2020;6:142-6.
 59. Fayiga FF, Reyes-Hadsall SC, Sebastiany LC, et al. (2021). Isotretinoin Associated Rhabdomyolysis: Monitoring Creatine Kinase and Educating Patients. *Skin appendage Disord* 2021;7:493-8.
 60. Kavadar G, Azman E, Tekdos Demircioğlu D, Emre T. Bilateral Sacroiliitis Due to Isotretinoin: Two Cases. 2015;2015:59-65.
 61. Pehlivan Y, Kisacik B, Sayiner ZA, Onat AM. Inflammatory back pain in patients treated with isotretinoin. *J Rheumatol* 2011;38:2690.
 62. Kocak O, Kocak AY, Sanal B, Kulan G. Bilateral Sacroiliitis Confirmed with Magnetic Resonance Imaging during Isotretinoin Treatment: Assessment of 11 Patients and a Review of the Literature. *Acta Dermatovenerol Croat* 2017;25:228-33.

Supplementary materials:

Supplementary Table 1. Characters of included analytical reports (n=13).

Supplementary Table 2. Characters of included case reports (n=28).

Supplementary Table 3. Characters of included case series (n=8; cases=54).